Evidence map›Paper›PMID 39410869›Full record

ArticleHistology and histopathology2025

DNMT1 silencing induces KIR2DL1/2/3 expression via methylation to alleviate graft-

Ping Zhang, Shuling Yu, Miao Zhou, Xiao Yan, Huiling Zhu, Lixia Sheng, Yi Zhang, Shujun Yang, Guifang Ouyang

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ping Zhang *Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China. fyyzhangping@nbu.edu.cn.
Shuling Yu *Health Science Center, Ningbo University, Ningbo, Zhejiang Province, PR China.
Miao ZhouDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China.
Xiao YanDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China.
Huiling ZhuDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China.
Lixia ShengDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China.
Yi ZhangStem Cell Transplantation Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China.
Shujun YangMedical Research Center, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, PR China.
Guifang OuyangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo First Hospital, Ningbo, Zhejiang Province, PR China. fyyouyangguifang@nbu.edu.cn.

Funding

Zhejiang Medical Health Science and Technology Project 2021KY282Zhejiang Medical Health Science and Technology Project 2022KY316
6 · The paper itself

Abstract

Natural killer (NK) cells are the promoters in graft-

Indexed as

DNA (Cytosine-5-)-Methyltransferase 1Graft vs Host DiseaseHematopoietic Stem Cell TransplantationKiller Cells, NaturalReceptors, KIR2DL1AnimalsDisease Models, AnimalDNA MethylationGene SilencingMiceMice, Inbred BALB CMice, Inbred C57BLTransplantation, HomologousDNA (Cytosine-5-)-Methyltransferase 1Dnmt1 protein, mouseReceptors, KIR2DL1

Identifiers

PMID39410869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.